• English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • français 
    • English
    • Ελληνικά
    • Deutsch
    • français
    • italiano
    • español
  • Ouvrir une session
Voir le document 
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
  •   Accueil de DSpace
  • Επιστημονικές Δημοσιεύσεις Μελών ΠΘ (ΕΔΠΘ)
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ.
  • Voir le document
JavaScript is disabled for your browser. Some features of this site may not work without it.
Tout DSpace
  • Communautés & Collections
  • Par date de publication
  • Auteurs
  • Titres
  • Sujets

Mitogen-inducible gene-2 (MIG2) and migfilin expression is reduced in samples of human breast cancer

Thumbnail
Auteur
Gkretsi, V.; Papanikolaou, V.; Zacharia, L. C.; Athanassiou, E.; Wu, C.; Tsezou, A.
Date
2013
Sujet
Breast cancer
MIG2
Migfilin
Mitogen-inducible gene-2
messenger RNA
migfilin protein
mitogen inducible gene 2
protein
unclassified drug
article
cancer tissue
clinical article
comparative study
female
human
human cell
human tissue
priority journal
protein expression
real time polymerase chain reaction
Western blotting
Blotting, Western
Breast
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Carcinoma, Lobular
Cell Adhesion Molecules
Cytoskeletal Proteins
Humans
Membrane Proteins
Neoplasm Invasiveness
Neoplasm Proteins
Prognosis
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger
Tumor Markers, Biological
Afficher la notice complète
Résumé
Background: Cell adhesion proteins that connect each cell to neighboring cells and the extracellular matrix play a fundamental role in metastasis. Mitogen-inducible gene-2 (MIG2), is a cell-matrix adhesion protein, which through migfilin, interacts with filamin-A, being linked to actin cytoskeleton. Aim: Recent studies have implicated both MIG2 and migfilin in cancer, but little is known regarding their expression in breast cancer. In this study, we investigated this topic. Materials and Methods: mRNA and protein expression was examined in 30 breast cancer samples and compared to that of normal adjacent tissue using real time-polymerase chain reaction (PCR) and western blotting. Results: Our results showed that expression of MIG2 and migfilin was significantly reduced in the majority of the breast cancer tissues compared to normal tissues regardless of metastatic status and disease stage. Conclusion: Both MIG2 and migfilin are down-regulated in breast cancer.
URI
http://hdl.handle.net/11615/28013
Collections
  • Δημοσιεύσεις σε περιοδικά, συνέδρια, κεφάλαια βιβλίων κλπ. [19735]

Related items

Showing items related by title, author, creator and subject.

  • Thumbnail

    Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer 

    Dimitrakopoulos F.-I., Kottorou A., Tzezou A. (2021)
    Despite the enormous advances during the last three decades, breast cancer continues to be the most frequent type of cancer as well as one of the most frequent cancer-related causes of death in women. Therapeutic management ...
  • Thumbnail

    Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes 

    Kotoula V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., Lakis S., Pentheroudakis G., Bobos M., Papadopoulou K., Tsolaki E., Pectasides D., Lazaridis G., Koutras A., Aravantinos G., Christodoulou C., Papakostas P., Markopoulos C., Zografos G., Papandreou C., Fountzilas G. (2016)
    The purpose of this study is to investigate whether the outcome of breast cancer (BC) patients treated with adjuvant chemotherapy is affected by co-mutated TP53 and PIK3CA according to stromal tumor-infiltrating lymphocytes ...
  • Thumbnail

    TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting 

    Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M.-A., Kotoula V. (2016)
    Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...
htmlmap 

 

Parcourir

Tout DSpaceCommunautés & CollectionsPar date de publicationAuteursTitresSujetsCette collectionPar date de publicationAuteursTitresSujets

Mon compte

Ouvrir une sessionS'inscrire
Help Contact
DepositionAboutHelpContactez-nous
Choose LanguageTout DSpace
EnglishΕλληνικά
htmlmap